You could argue that anything done in a new way, however small, can be counted as an innovation. Introducing innovation at a game-changing level, however, is not so simple, and it's only going to get harder for the pharmaceutical industry.
Blog
Where our team of guest writers discuss what they think about the current NGP US Issues.
Director of Business Development
Can digital pathology save drug development?
Peter Duncan of Definiens discusses the potential of digital pathology.07 Jul 2010
Editor's Blog
Can digital pathology save drug development?
Let’s start with what we know. For years, the state of pharmaceutical drug development has been in decline in terms of new molecular entities or biologics that are clearing FDA approval.
It’s common knowledge that the pharmaceutical industry is in the throes of change. The blockbuster model it has relied upon for decades is no longer viable, but what will take its place? Finding a niche area, perhaps, or going after orphan drugs, or moving into emerging markets.
What will the rise of generics mean for the pharmaceutical industry?
Generics are on the rise again. Thanks to President Obama’s decision to increase access to them as a way of bringing less expensive treatments to the American public, the generics star is once again in the ascendant, and their production is now nearly 100 percent of their branded rivals.
What will this mean for the pharmaceutical industry? It depends on your point of view.
Source: www.ngpharma.com© 2010 GDS Publishing Ltd. All rights reserved.